Ignyta: latest news - GoINPHARMA
Wednesday, 23 January 2019 - 23:16

Ignyta

Acquisition of Ignyta fetches almost $100m to Teva from Roche

Israel-based Teva has unexpectedly received a cash injection as Roche has acquired Ignyta for $1.7bn, thanks to Teva owning 5% of the American biotech’s shares. Teva sold to Ignyta the rights to four cancer drugs in March 2015, in return…

Roche’s and Bayer’s strategies compared

If we compare the pipelines and M&A activities of Germany-based Bayer and Switzerland-based Roche, it is clear that the strategies developed by the two groups have much in common.  Bayer signed on November 14th an agreement with Loxo Oncology worth…

Roche pursuing M&A again: Ignyta acquired for $1.7bn

Switzerland-based Roche today has surprised the market as it has announced the acquisition of California-based (San Diego) Ignyta for $1.7bn. Ignyta was founded in 2011 and focuses on the so-called Precision Therapeutics area, addressing the challenge to find treatments to…